SCHEMBL4807526

SCHEMBL4807526

CC[C@H](C)[C@H](OCc1cc(F)cc(F)c1)C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
POLB P06746 2/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
TSHR P16473 1/20 0.35
MAOB P27338 1/20 0.35
IDO1 P14902 2/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP12 P39900 1/20 0.35
GSK3B P49841 1/20 0.35
BACE1 P56817 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
SLC6A3 Q01959 1/20 0.34
GAA P10253 1/20 0.34
PSEN1 P49768 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4807531 1.00 NOS3 (0.39) NOS3NOS1NOS2POLBALDH1A1
SCHEMBL4800718 0.85 SLC1A2 (0.39) MAOBIDO1MMP1MMP2MMP9
SCHEMBL4803814 0.79 MEN1 (0.49) ALDH1A1MAPTMEN1KMT2A
SCHEMBL4803808 0.79 MEN1 (0.49) ALDH1A1MAPTMEN1KMT2A
SCHEMBL13500200 0.75 IDO1 (0.38) MAOBIDO1MMP1MMP2MMP9
SCHEMBL13461436 0.74 MAOB (0.35) TSHRMAOBIDO1MMP1MMP2
SCHEMBL4803552 0.73 POLB (0.44) NOS3NOS1NOS2POLBALDH1A1
SCHEMBL4803558 0.73 POLB (0.44) NOS3NOS1NOS2POLBALDH1A1
SCHEMBL13499757 0.72 IDO1 (0.36) MAOBIDO1GSK3BBACE1SLC6A3
SCHEMBL4803004 0.72 IDO1 (0.38) MAOBIDO1GSK3BBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446125-B2 Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders UNIVERSIDAD DEL PAIS VASCO (ES) 2008-11-04 US disclosed
US-20060211630-A1 Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders UNIVERSIDAD DEL PAIS VASCO (ES) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211630-A1 Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders ITGB5, ITGA5, ITGAV NOS3 235/4885NOS1 195/4885NOS2 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.